vs
Side-by-side financial comparison of NATIONAL RESEARCH CORP (NRC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $18.6M, roughly 1.9× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 5.1%, a 60.6% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -4.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -0.2%).
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NRC vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $18.6M |
| Net Profit | $1.8M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 13.3% | 56.3% |
| Net Margin | 5.1% | 65.7% |
| Revenue YoY | -4.6% | 1808.5% |
| Net Profit YoY | -72.6% | 376.5% |
| EPS (diluted) | $49.58 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $18.6M | ||
| Q3 25 | $34.6M | $334.0K | ||
| Q2 25 | $34.0M | $1.4M | ||
| Q1 25 | $33.6M | $257.0K | ||
| Q4 24 | $36.9M | $977.0K | ||
| Q3 24 | $35.8M | $660.0K | ||
| Q2 24 | $35.0M | $736.0K | ||
| Q1 24 | $35.3M | $1.4M |
| Q4 25 | $1.8M | $12.3M | ||
| Q3 25 | $4.1M | $-8.6M | ||
| Q2 25 | $-106.0K | $-6.9M | ||
| Q1 25 | $5.8M | $-5.4M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $5.7M | $-2.8M | ||
| Q2 24 | $6.2M | $-14.5M | ||
| Q1 24 | $6.4M | $411.0K |
| Q4 25 | 13.3% | 56.3% | ||
| Q3 25 | 22.4% | -2516.5% | ||
| Q2 25 | 4.7% | -701.0% | ||
| Q1 25 | 25.6% | -3350.2% | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 22.3% | -1563.6% | ||
| Q2 24 | 25.3% | -1255.0% | ||
| Q1 24 | 24.8% | -692.5% |
| Q4 25 | 5.1% | 65.7% | ||
| Q3 25 | 11.9% | -2572.2% | ||
| Q2 25 | -0.3% | -504.8% | ||
| Q1 25 | 17.2% | -2097.7% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 15.9% | -425.5% | ||
| Q2 24 | 17.6% | -1964.4% | ||
| Q1 24 | 18.0% | 29.9% |
| Q4 25 | $49.58 | $0.25 | ||
| Q3 25 | $0.18 | $-0.17 | ||
| Q2 25 | $-0.01 | $-0.14 | ||
| Q1 25 | $0.25 | $-0.11 | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $0.24 | $-0.06 | ||
| Q2 24 | $0.26 | $-0.30 | ||
| Q1 24 | $0.27 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.0M | $49.4M |
| Total Assets | $134.9M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $40.0M | ||
| Q3 25 | $2.2M | $37.9M | ||
| Q2 25 | $5.3M | $44.8M | ||
| Q1 25 | $2.5M | $40.6M | ||
| Q4 24 | $4.2M | $59.3M | ||
| Q3 24 | $3.5M | $68.8M | ||
| Q2 24 | $485.0K | $73.0M | ||
| Q1 24 | $1.7M | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $35.2M | — |
| Q4 25 | $14.0M | $49.4M | ||
| Q3 25 | $14.3M | $36.4M | ||
| Q2 25 | $21.3M | $44.5M | ||
| Q1 25 | $29.7M | $50.5M | ||
| Q4 24 | $31.3M | $55.1M | ||
| Q3 24 | $34.6M | $58.5M | ||
| Q2 24 | $40.2M | $60.4M | ||
| Q1 24 | $36.9M | $74.1M |
| Q4 25 | $134.9M | $59.0M | ||
| Q3 25 | $135.7M | $51.1M | ||
| Q2 25 | $141.4M | $60.7M | ||
| Q1 25 | $135.2M | $67.9M | ||
| Q4 24 | $132.5M | $90.6M | ||
| Q3 24 | $131.8M | $99.0M | ||
| Q2 24 | $119.1M | $107.8M | ||
| Q1 24 | $120.9M | $118.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $7.2M | $18.4M |
| Free Cash FlowOCF − Capex | $6.1M | — |
| FCF MarginFCF / Revenue | 17.2% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 3.99× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $15.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.2M | $18.4M | ||
| Q3 25 | $13.8M | $-8.7M | ||
| Q2 25 | $-1.1M | $-7.5M | ||
| Q1 25 | $6.6M | $-7.5M | ||
| Q4 24 | $6.4M | $-24.0M | ||
| Q3 24 | $9.4M | $765.0K | ||
| Q2 24 | $6.8M | $-10.9M | ||
| Q1 24 | $12.0M | $-4.0M |
| Q4 25 | $6.1M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $-4.1M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.9M | — |
| Q4 25 | 17.2% | — | ||
| Q3 25 | 29.4% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 22.4% | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 8.9% | — | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | 3.99× | 1.50× | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NRC
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
